home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

Valeritas

Undisclosed

Medical Device
Endocrinology

Apr2
2014
Zealand Pharma Completes the Acquisition of Valeritas »

Apr24
2014
Valeritas Announces Pricing of $24 Million Public Offering of Common Stock »

Mar23
2014
Valeritas Announces Pricing of $52.5 Million Public Offering of Common Stock »

Feb15
2014
Valeritas and its Secured Creditors Agree to Convert $27.5 Million of Debt into Preferred Stock »

Feb9
2014
Valeritas Amends Existing Credit Facility to Extend Payment Obligations »

Nov30
2014
Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors »

Sep22
2014
Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors »

Jul13
2014
Valeritas Appoints Brian K. Roberts to its Board of Directors »

May4
2014
Valeritas Completes Alternative Public Offering and Raises Gross Proceeds of $25.2 Million »

Apr25
2014
Peter J. Devlin Joins Valeritas Board of Directors as Independent Director »

BRIDGEWATER, New Jersey, April 25, 2016 – Valeritas, Inc. announced today that Peter J. Devlin has been elected to the company's Board of Directors as an independent director. Peter has more than 27 years of broad-based experience in the medical device and in-vitro diagnostics industries as well as extensive knowledge and expertise in diabetes. In addition, he has had great success with commercializing products that have a direct patient use connection.

 

"Peter is a highly motivated, growth-driven leader with proven ability to develop and implement successful strategies for global healthcare markets across a variety of medical specialties. His breadth of commercial operational experience and his ability to develop and execute strategic partnerships will be extremely valuable to the Valeritas board," said John Timberlake, President and CEO at Valeritas. "We are thrilled to welcome Peter to the Board, and we are certain that he will make significant contributions to the future growth of Valeritas."

 

Peter provides advisory services to life science and healthcare venture capital firms. He is the former Chief Commercial Officer of Insulet Corporation where he led the development of Insulet’s strategic and commercial plans, which resulted in an increase of annual sales from approximately $30M to nearly $300M. Prior to Insulet, Peter held various senior level positions in diabetes care at Abbott Laboratories Inc. including Divisional Vice President, Global Strategic Marketing; General Manager - Hospital & Government; general management responsibility for the Canadian Diabetes/POC business unit and Marketing Director, US Consumer Blood Glucose Monitoring. Mr. Devlin earned his bachelor’s of science degree in mechanical engineering from the University of Massachusetts.

 

"Valeritas' V-Go® Disposable Insulin Delivery device is clearly making a positive impact on the lives of patients with Type 2 diabetes. The fact that V-Go has strong reimbursement coverage at the pharmacy for both commercial and Medicare Part D patients is remarkable. The distinct advantage is the ease and convenience which patients can acquire V-Go with their insulin at the pharmacy," said Peter. "I am excited to work with John and the Valeritas team and look forward to contributing to their continued growth and success."

 

About Valeritas, Inc.

Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, the V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate infusion of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery system on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

 

Press Contact:
Marjie Hadad
MH Communications
PR@valeritas.com
908-947-0378

Apr19
2014
Rodney D. Altman, MD Joins Valeritas Board of Directors »

Feb25
2014
Valeritas Announces Leadership and Board of Directors Changes »

Jun14
2014
Valeritas Closes $100 Million Financing »